Don W. Shaffer

Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network

John D. Hainsworth, Sharlene Litchy, Don W. Shaffer et al. · Journal of Clinical Oncology · 2005 · 331 citations

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.

Howard A. Burris, Rebecca Irvin, John G. Kuhn et al. · Journal of Clinical Oncology · 1993 · 135 citations

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

James G. Wall, Howard A. Burris, Daniel D. Von Hoff et al. · Anti-Cancer Drugs · 1992 · 113 citations

Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer

Anthony A. Meluch, F. Anthony Greco, James R. Gray et al. · The Cancer Journal · 2003 · 104 citations

Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial

F. Anthony Greco, Gladys Rodriguez, Don W. Shaffer et al. · The Oncologist · 2004 · 53 citations · Full text